A Phase 1/2 interventional study of AstroStem and Placebo-Control in Alzheimer Disease, sponsored by Nature Cell Co. Ltd.. Completed at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-08-10.
Sponsored by Nature Cell Co. Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,271st largest by enrollment of the 1,610 interventional ones that give a count, is one of 69 that started in 2017, is one of 67 in phase 1/2, and was the 863rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 69 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
Nature Cell Co. Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Nature Cell Co. Ltd. has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: AstroStem
Other: Placebo-Control
Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
Saline with 30% auto-serum
Treatment Related Adverse Events
Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results
Time frame: 30 Weeks
ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)
Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment
Time frame: Baseline and 30 Weeks
MMSE (Mini-mental Status Examination)
Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.
Time frame: Baseline and 30 Weeks
CDR-SOB (Clinical Dementia Rating-Sum of Boxes)
Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia
Time frame: Baseline and 30 Weeks
NPI (Neuropsychiatric Inventory)
Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.
Time frame: Baseline and 30 Weeks
GDS (Geriatric Depression Scale)
Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
Time frame: Baseline and 30 Weeks
ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)
Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.
Time frame: Baseline and 30 Weeks
C-SSRS (Columbia Suicide Severity Rating Scale)
Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.
Time frame: Baseline and 30 Weeks
| Milestone | AstroStem | Placebo-Control |
|---|---|---|
| Started | 11 | 10 |
| Completed | 7 | 5 |
| Not completed | 4 | 5 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 4 |
Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results
| Participants | AstroStem | Placebo-Control |
|---|---|---|
| Treatment Related Adverse Events | 6 | 3 |
Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale) | 5.9 ± 6.8 | 3.0 ± 5.4 |
Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| MMSE (Mini-mental Status Examination) | -3.4 ± 2.8 | -1.4 ± 2.8 |
Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| CDR-SOB (Clinical Dementia Rating-Sum of Boxes) | 1.3 ± 1.7 | 0.9 ± 1.5 |
Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| NPI (Neuropsychiatric Inventory) | -1.4 ± 8.5 | -5.7 ± 11.5 |
Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| GDS (Geriatric Depression Scale) | -0.3 ± 1.3 | 0.3 ± 2.1 |
Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living) | -4.4 ± 9.0 | -4.7 ± 9.8 |
Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.
| score on a scale | AstroStem | Placebo-Control |
|---|---|---|
| C-SSRS (Columbia Suicide Severity Rating Scale) | -2.1 ± 6.6 | 0.0 ± 0.0 |
Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AstroStem | 0/11 (0%) | 3/11 (27.3%) | 3/11 (27.3%) |
| Placebo-Control | 0/10 (0%) | 1/10 (10%) | 2/10 (20%) |
| Event | AstroStem | Placebo-Control |
|---|---|---|
| Acute Pulmonary OedemaInfections and infestations | 0/11 | 1/10 |
| oesophageal squamous cell carcinoma stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/11 | 0/10 |
| diarrheaGastrointestinal disorders | 1/11 | 0/10 |
| pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/11 | 0/10 |
| Event | AstroStem | Placebo-Control |
|---|---|---|
| Gastrointestinal Reflux DiseaseGastrointestinal disorders | 0/11 | 1/10 |
| Oedema PeripheralGeneral disorders | 0/11 | 1/10 |
| PainGeneral disorders | 0/11 | 1/10 |
| PyrexiaGeneral disorders | 0/11 | 1/10 |
| DehydrationMetabolism and nutrition disorders | 1/11 | 1/10 |
| HypokalaemiaMetabolism and nutrition disorders | 0/11 | 1/10 |
| AgitationPsychiatric disorders | 0/11 | 1/10 |
| NasopharyngitisInfections and infestations | 0/11 | 1/10 |
| PneumoniaInfections and infestations | 0/11 | 1/10 |
| Open Angle GlaucomaEye disorders | 1/11 | 0/10 |
| Age, Continuous(years) | AstroStem | Placebo-Control | Total |
|---|---|---|---|
| Mean | 72.4 ± 7.6 | 75.6 ± 8.2 | 73.9 ± 7.6 |
| Sex: Female, Male(Participants) | AstroStem | Placebo-Control | Total |
|---|---|---|---|
| Female | 4 | 5 | 9 |
| Male | 7 | 5 | 12 |
| Race/Ethnicity, Customized(Participants) | AstroStem | Placebo-Control | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 3 |
| Not-Hispanic or Latino | 9 | 9 | 18 |
| White | 10 | 9 | 19 |
| Black or African American | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 0 | 0 |
| Height(cm) | AstroStem | Placebo-Control | Total |
|---|---|---|---|
| Mean | 167.9 ± 14.4 | 168.3 ± 9.7 | 168.1 ± 12.1 |
| Weight(kg) | AstroStem | Placebo-Control | Total |
|---|---|---|---|
| Mean | 74.8 ± 17.2 | 64.6 ± 12.0 | 69.9 ± 15.5 |
| BMI(kg/m^2) | AstroStem | Placebo-Control | Total |
|---|---|---|---|
| Mean | 26.3 ± 4.3 | 22.8 ± 3.5 | 24.6 ± 4.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2017 to primary completion in Jun 2019, 25 months.
Results were first posted in Jul 2021, 2 years after primary completion.
Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nature Cell Co. Ltd.